世界最新医学信息文摘(连续型电子期刊)
世界最新醫學信息文摘(連續型電子期刊)
세계최신의학신식문적(련속형전자기간)
World Latest Medicine Information
2015年
17期
27-27,37
,共2页
宋志军%王晓兵%刘巍%刘永青%刘建香
宋誌軍%王曉兵%劉巍%劉永青%劉建香
송지군%왕효병%류외%류영청%류건향
慢性阻塞性肺疾病%糖皮质激素%急性加重期
慢性阻塞性肺疾病%糖皮質激素%急性加重期
만성조새성폐질병%당피질격소%급성가중기
Chronic obstructive pulmonary disease%Glucocorticoid%Acute exacerbation
目的:观察全身应用糖皮质激素在治疗慢性阻塞性疾病(COPD)急性加重期的作用。方法:选取我院自2013年12月至2014年12月所收治的68例COPD急性加重期患者患者作为研究对象,随机分为对照组和观察组,各34例。对照组实施常规治疗,观察组在常规治疗基础上给予全身性糖皮质激素治疗,分析比较两组患者治疗前后的运动耐力和呼吸困难改善情况。结果:治疗后,观察组患者在运动耐力评分和呼吸困难评分方面均显著优于对照组,P<0.05,差异具有统计学意义。结论:全身应用糖皮质激素对COPD急性加重期患者临床症状改善具有重要意义,利于患者早日康复,值得临床推广。
目的:觀察全身應用糖皮質激素在治療慢性阻塞性疾病(COPD)急性加重期的作用。方法:選取我院自2013年12月至2014年12月所收治的68例COPD急性加重期患者患者作為研究對象,隨機分為對照組和觀察組,各34例。對照組實施常規治療,觀察組在常規治療基礎上給予全身性糖皮質激素治療,分析比較兩組患者治療前後的運動耐力和呼吸睏難改善情況。結果:治療後,觀察組患者在運動耐力評分和呼吸睏難評分方麵均顯著優于對照組,P<0.05,差異具有統計學意義。結論:全身應用糖皮質激素對COPD急性加重期患者臨床癥狀改善具有重要意義,利于患者早日康複,值得臨床推廣。
목적:관찰전신응용당피질격소재치료만성조새성질병(COPD)급성가중기적작용。방법:선취아원자2013년12월지2014년12월소수치적68례COPD급성가중기환자환자작위연구대상,수궤분위대조조화관찰조,각34례。대조조실시상규치료,관찰조재상규치료기출상급여전신성당피질격소치료,분석비교량조환자치료전후적운동내력화호흡곤난개선정황。결과:치료후,관찰조환자재운동내력평분화호흡곤난평분방면균현저우우대조조,P<0.05,차이구유통계학의의。결론:전신응용당피질격소대COPD급성가중기환자림상증상개선구유중요의의,리우환자조일강복,치득림상추엄。
Objective: To observe systemic administration of corticosteroid in the treatment of chronic obstructive pulmonary disease ( COPD) exacerbation. Methods: 68 patients who came to our hospital for the treatment of acute exacerbations of COPD from December 2013 to December 2014 were randomly divided into an observation group and a control group, with 34 cases in each group. Control group received routine treatment and observation group was treated with the routine therapy and the systemic corticosteroids. Then the exercise endurance and breathing difficulty extent before and after treatment of the two groups were compared . Results:After treatment, the exercise tolerance score and Dyspnoea score of the observation group were signifi-cantly better than those of the control group ( P<0.05) , and it has a statistically significant difference. Conclusion: systemic Corticoid is important for improvement of clinical symptoms in patients with acute exacerbation of COPD, which will accelerate patients' recovery. Therefore, it is worthy of promotion.